我國(guo)(guo)的甾(zai)體激素(su)藥(yao)(yao)(yao)物(wu)(wu)(wu)(wu)（主(zhu)要包括糖皮質激素(su)，性(xing)(xing)激素(su)和避孕藥(yao)(yao)(yao)）生(sheng)(sheng)(sheng)產(chan)，是(shi)從1958年(nian)(nian)(nian)以來開始(shi)研(yan)發(fa)，同于歐美國(guo)(guo)家初期階(jie)段采用(yong)的以植源性(xing)(xing)薯蕷皂(zao)素(su)為起始(shi)原(yuan)料(liao)，經由(you)化(hua)學(xue)(xue)合成和生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)制造（微生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)11-羥(qian)(qian)(qian)(qian)基化(hua)和/或1,2-脫氫，以及16位羥(qian)(qian)(qian)(qian)基化(hua)，近年(nian)(nian)(nian)的15位羥(qian)(qian)(qian)(qian)基化(hua)和4AD的9位羥(qian)(qian)(qian)(qian)基化(hua)）生(sheng)(sheng)(sheng)產(chan)皮質激素(su)類(lei)(lei)(lei)性(xing)(xing)激素(su)及新型避孕藥(yao)(yao)(yao)(59年(nian)(nian)(nian)甾(zai)類(lei)(lei)(lei)原(yuan)料(liao)藥(yao)(yao)(yao)實現全(quan)(quan)(quan)合成工業(ye)化(hua))等都有了快速發(fa)展。90’年(nian)(nian)(nian)代以來全(quan)(quan)(quan)球(qiu)(qiu)甾(zai)體激素(su)黃(huang)金時(shi)代——銷售額(e)年(nian)(nian)(nian)遞增10-15%；國(guo)(guo)內僅糖皮質激素(su)原(yuan)料(liao)藥(yao)(yao)(yao)企32家，批文110；耗用(yong)薯蕷皂(zao)素(su)每年(nian)(nian)(nian)2000噸(dun)，銷售收入百(bai)億(yi)元(yuan)，國(guo)(guo)內份(fen)額(e)5%。故甾(zai)體激素(su)藥(yao)(yao)(yao)物(wu)(wu)(wu)(wu)的剛性(xing)(xing)需(xu)求推動藥(yao)(yao)(yao)物(wu)(wu)(wu)(wu)市場在世界(jie)藥(yao)(yao)(yao)物(wu)(wu)(wu)(wu)之林中有“穩如磐石不可或缺(que)”之說，僅以四大(da)基礎皮質激素(su)類(lei)(lei)(lei)原(yuan)料(liao)藥(yao)(yao)(yao)據2007年(nian)(nian)(nian)《Brok微生(sheng)(sheng)(sheng)物(wu)(wu)(wu)(wu)學(xue)(xue)》第十版提(ti)供的數據全(quan)(quan)(quan)球(qiu)(qiu)每年(nian)(nian)(nian)生(sheng)(sheng)(sheng)產(chan)量超過(guo)800噸(dun)；我國(guo)(guo)2001年(nian)(nian)(nian)成都彭州全(quan)(quan)(quan)國(guo)(guo)甾(zai)體激素(su)藥(yao)(yao)(yao)物(wu)(wu)(wu)(wu)會議上，天(tian)津醫藥(yao)(yao)(yao)盧(lu)彥昌報告當(dang)時(shi)我國(guo)(guo)四大(da)基礎皮質激素(su)類(lei)(lei)(lei)原(yuan)料(liao)藥(yao)(yao)(yao)生(sheng)(sheng)(sheng)產(chan)量已達130噸(dun)，占全(quan)(quan)(quan)球(qiu)(qiu)產(chan)量的三分之一(yi)。